EP 2673298 A1 20131218 - ANTI-GB3 ANTIBODIES USEFUL IN TREATING DISORDERS ASSOCIATED WITH ANGIOGENESIS
Title (en)
ANTI-GB3 ANTIBODIES USEFUL IN TREATING DISORDERS ASSOCIATED WITH ANGIOGENESIS
Title (de)
ANTI-GB3-ANTIKÖRPER ZUR BEHANDLUNG VON ERKRANKUNGEN IM ZUSAMMENHANG MIT ANGIOGENESE
Title (fr)
ANTICORPS ANTI-GB3 UTILES DANS LE TRAITEMENT DES MALADIES ASSOCIÉES À L'ANGIOGÉNÈSE
Publication
Application
Priority
- FR 1150958 A 20110207
- EP 2012052004 W 20120207
Abstract (en)
[origin: WO2012107424A1] The present invention is situated within the field of novel anti-cancer therapies, specifically within the field of anti-angiogenic molecules. It relates in particular to anti-GB3 antibodies having specific CDR sequences, as well as to the use of anti-GB3 antibodies not coupled to a therapeutic molecule in treating disorders associated with angiogenesis, such as solid tumors.
IPC 8 full level
C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/30 (2006.01)
CPC (source: EP US)
A61P 9/00 (2017.12 - EP); A61P 17/00 (2017.12 - EP); A61P 27/02 (2017.12 - EP); A61P 35/00 (2017.12 - EP); A61P 37/00 (2017.12 - EP); C07K 16/28 (2013.01 - EP US); C07K 16/2896 (2013.01 - EP US); C07K 16/30 (2013.01 - EP US); C07K 16/3084 (2013.01 - EP US); C07K 16/44 (2013.01 - EP US); C07K 2317/73 (2013.01 - EP US); C07K 2317/734 (2013.01 - EP US); C07K 2317/92 (2013.01 - EP US)
Citation (search report)
See references of WO 2012107424A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
FR 2971250 A1 20120810; EP 2673298 A1 20131218; US 2014044721 A1 20140213; WO 2012107424 A1 20120816
DOCDB simple family (application)
FR 1150958 A 20110207; EP 12703098 A 20120207; EP 2012052004 W 20120207; US 201213983937 A 20120207